[ CAS No. 156001-53-5 ] {[proInfo.proName]}

Name: 156001-53-5|5-Bromo-2-(bromomethyl)benzonitrile|95%
Brand: Ambeed
SKU: A103615
Price: 55.0 USD
Availability: InStock
Rating: 93 (25 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 156001-53-5 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 156001-53-5 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 156001-53-5 ]

SDS Specification

Alternatived Products of [ 156001-53-5 ]

Product Details of [ 156001-53-5 ]

CAS No. :	156001-53-5	MDL No. :	MFCD09261033
Formula :	C₈H₅Br₂N	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	RPQAJIVYLBTILC-UHFFFAOYSA-N
M.W :	274.94	Pubchem ID :	44203140
Synonyms :

Calculated chemistry of [ 156001-53-5 ]

Physicochemical Properties

Num. heavy atoms :	11
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.12
Num. rotatable bonds :	1
Num. H-bond acceptors :	1.0
Num. H-bond donors :	0.0
Molar Refractivity :	51.69
TPSA :	23.79 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.93 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.3
Log Po/w (XLOGP3) :	2.89
Log Po/w (WLOGP) :	3.06
Log Po/w (MLOGP) :	2.96
Log Po/w (SILICOS-IT) :	3.48
Consensus Log Po/w :	2.94

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.7
Solubility :	0.0545 mg/ml ; 0.000198 mol/l
Class :	Soluble
Log S (Ali) :	-3.05
Solubility :	0.245 mg/ml ; 0.000892 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-4.59
Solubility :	0.00705 mg/ml ; 0.0000256 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	2.3

Safety of [ 156001-53-5 ]

Signal Word:	Danger	Class:	8
Precautionary Statements:	P501-P260-P270-P271-P264-P280-P362+P364-P303+P361+P353-P301+P330+P331-P301+P312+P330-P304+P340+P310-P305+P351+P338+P310-P405	UN#:	3261
Hazard Statements:	H302+H312+H332-H314	Packing Group:	Ⅱ
GHS Pictogram:

Application In Synthesis of [ 156001-53-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 156001-53-5 ]
Downstream synthetic route of [ 156001-53-5 ]

[ 156001-53-5 ] Synthesis Path-Upstream 1~5

1
[ 156001-53-5 ]
[ 523977-64-2 ]

Yield	Reaction Conditions	Operation in experiment
52%	With trimethylamine-N-oxide In dichloromethane; dimethyl sulfoxide at 5 - 22℃; for 6 h;	[0467] To a stirred solution of trimethylamine N-oxide dihydrate (16.98 g, 152.8 mmol) in DM50 (60 mE) was added a solution of 5-bromo-2-(bromomethyl)benzonitrile (From step 1, 10.5 g, 38.19 mmol) in DCM (30 mE) slowly at 5° C. The resulting mixture was warmed up to 22° C. and stirred for further 6 h. The reaction was diluted with DCM (70 mE), washed with brine (20 mEx3), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel (0-16percent EtOAc in petroleum ether) to afford the title compound (4.2 g, yield 52percent) as a white solid. ‘H NMR (400 MHz, CDC13) ö 10.31 (s, 1H), 7.98 (s, 1H), 7.92 (s, 2H).

2
[ 156001-51-3 ]
[ 156001-53-5 ]

Yield	Reaction Conditions	Operation in experiment
70%	With N-Bromosuccinimide; dibenzoyl peroxide In tetrachloromethane at 80℃; for 8 h; Inert atmosphere	[0465] A mixture of 5-bromo-2-methylbenzonitrile (10.0 g, 51.01 mmol), N135 (9.99 g, 56.11 mmol) and benzoylperoxide (0.62 g, 2.6 mmol) in CC14 (100 mE) was stirred at 80° C. for 8 h under N2 atmosphere. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by column chromatography on silica gel (0.—Spercent EtOAc in petroleum ether) to afford the title compound (9.8 g, yield 70percent) as a light yellow oil. ‘H NMR (400 MHz, CDC13) ö 7.80 (d, J=2.0 Hz, 1H), 7.72 (dd, J=8.4, 2.0 Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 4.58 (s, 2H).
43%	at 60℃; for 16 h; Inert atmosphere	5-bromo-2-(bromomethyl)benzonitrile To a solution of 5-bromo-2-methylbenzonitrile (10.0 g, 51.0 mmol) in chloroform (150 mL) was added benzoperoxide (1.3 g, 5.07 mmol) and NBS (9.0 g, 50.0 mmol) at room temperature. The resulting solution was stirred for 16 h at 60° C., cooled to room temperature, and treated with water (100 mL). The resulting solution was extracted with ethyl acetate (300 mL*3). The organic phases were combined, washed with brine and dried over sodium sulfate. The solvent was removed under reduced pressure and the residue was purified by flash chromatography eluting with ethyl acetate in hexane (0percent to 5percent gradient) to yield 5-bromo-2-(bromomethyl)benzonitrile as purple solid (6.0 g, 43percent).
38%	With N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) In tetrachloromethane for 1.25 h; Heating / reflux	Step 4: 5-Bromo-2-bromomethvlbenzonitrile: A mixture of 5-bromo-2-methylbenzonitrile (5.0 g, 25.5 mmol), N-bromosuccinimide (4.54 g, 25.5 mmol), 2',2'-azobis (2- methylpropionitrile) (0.05 g) and carbon tetrachloride (25 mL) is heated at reflux for 75 min. After cooling to room temperature, the solids are removed by filtration. The filtrate is concentrated and the residue purified by chromatography eluting with cyclohexane-20percent ethyl acetate. Product containing fractions are combined and concentrated to afford 5-bromo-2- bromomethylbenzonitrile (2.69 g, 38percent). LC/MS: MS showed no parent molecular ion peak; RT 3.52 min.

Reference： [1] Organic Letters, 2003, vol. 5, # 7, p. 1131 - 1134
[2] Journal of Materials Chemistry, 2011, vol. 21, # 26, p. 9523 - 9531
[3] Patent: US2017/362228, 2017, A1, . Location in patent: Paragraph 0464; 0465
[4] ACS Medicinal Chemistry Letters, 2018, vol. 9, # 2, p. 120 - 124
[5] Patent: US2016/376283, 2016, A1, . Location in patent: Paragraph 0341; 0342
[6] Patent: WO2005/97750, 2005, A1, . Location in patent: Page/Page column 69-70
[7] Patent: WO2014/151761, 2014, A1, . Location in patent: Page/Page column 106
[8] Patent: WO2015/89327, 2015, A1, . Location in patent: Paragraph 0206
[9] Patent: US9586928, 2017, B2, . Location in patent: Page/Page column 163; 164

3
[ 939-83-3 ]
[ 156001-53-5 ]

Reference： [1] Organic Letters, 2003, vol. 5, # 7, p. 1131 - 1134
[2] Journal of Materials Chemistry, 2011, vol. 21, # 26, p. 9523 - 9531

4
[ 50670-64-9 ]
[ 156001-53-5 ]

Reference： [1] Organic Letters, 2003, vol. 5, # 7, p. 1131 - 1134
[2] Journal of Materials Chemistry, 2011, vol. 21, # 26, p. 9523 - 9531

5
[ 529-19-1 ]
[ 156001-53-5 ]

Reference： [1] Journal of Materials Chemistry, 2011, vol. 21, # 26, p. 9523 - 9531

[ 156001-53-5 ] Synthesis Path-Downstream 1~87

1
[ 156001-53-5 ]
[ 523977-67-5 ]

Reference： [1]Organic Letters,2003,vol. 5,p. 1131 - 1134

2
[ 156001-53-5 ]
[ 523977-68-6 ]

Reference： [1]Organic Letters,2003,vol. 5,p. 1131 - 1134
[2]Organic Letters,2003,vol. 5,p. 1131 - 1134

3
[ 156001-53-5 ]
[ 523977-70-0 ]

Reference： [1]Organic Letters,2003,vol. 5,p. 1131 - 1134

4
[ 156001-53-5 ]
5-[(E)-2-(4-Diphenylamino-phenyl)-vinyl]-2-((E)-2-{4-[(E)-2-(4-diphenylamino-phenyl)-vinyl]-phenyl}-vinyl)-benzonitrile [ No CAS ]

Reference： [1]Organic Letters,2003,vol. 5,p. 1131 - 1134

5
[ 156001-53-5 ]
4,4'-Bis-[(E)-2-(4-diphenylamino-phenyl)-vinyl]-biphenyl-3,3'-dicarbonitrile [ No CAS ]

Reference： [1]Organic Letters,2003,vol. 5,p. 1131 - 1134

6
[ 156001-53-5 ]
C₅₆H₄₀N₄ [ No CAS ]

Reference： [1]Organic Letters,2003,vol. 5,p. 1131 - 1134

7
[ 156001-53-5 ]
C₅₆H₄₀N₄ [ No CAS ]

Reference： [1]Organic Letters,2003,vol. 5,p. 1131 - 1134
[2]Organic Letters,2003,vol. 5,p. 1131 - 1134

8
[ 110-91-8 ]
[ 156001-53-5 ]
[ 867006-59-5 ]

Yield	Reaction Conditions	Operation in experiment
74%		Step 5: 5-Bromo-2-(morpholin-4-yl)methvlbenzonitrile: 5-Bromo-2- bromomethylbenzonitrile (2.50 g, 9.1 mmol) is added portionwise to a stirred solution of morpholine (828 muL, 9.5 mmol) and triethylamine (1.27 mL, 9.1 mmol) in methanol (2 mL). After 4 hr, the solvent is removed and the residue is suspended in water that is made basic with sodium hydroxide and then extracted with ethyl acetate. The extract is dried, filtered, and concentrated to give 5-bromo-2- (morpholin-4-yl)methylbenzonitrile g, 74%) as a cream solid.
25%	With triethylamine; In methanol; at 20℃; for 8h;Inert atmosphere;	5-bromo-2-(morpholinomethyl)benzonitrile (0265) To a solution of <strong>[156001-53-5]5-bromo-2-(bromomethyl)benzonitrile</strong> (318 mg, 1.16 mmol) in methanol (10 mL) were added morpholine (100 mg, 1.15 mmol) and triethylamine (116 mg, 1.15 mmol) at room temperature. The resulting solution was stirred for 8 h at room temperature and then treated with water (20 mL). The resulting mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with brine and dried over sodium sulfate. The solvent was removed under reduced pressure to yield 5-bromo-2-(morpholin-4-ylmethyl)benzonitrile as yellow solid (80 mg, 25%). MS: m/z=281.0 [M+H]+.

Reference： [1]Patent: WO2005/97750,2005,A1 .Location in patent: Page/Page column 70
[2]Patent: US2016/376283,2016,A1 .Location in patent: Paragraph 0263; 0265

Yield	Reaction Conditions	Operation in experiment
28.7%		EXAMPLE XVII 3-Bromo-6-bromomethyl-benzonitrile STR27 A suspension of 19.1 g (97.4 mmol) of the compound from Example XVI, 17.3 g (97.4 mmol) of N-bromosuccinimide and 0.2 g of azobisisobutyronitrile in 100 ml of carbon tetrachloride is stirred under reflux for 1 hour. The mixture is filtered, the filtrate is concentrated to dryness and the residue is crystallized from methanol to give 7.7 g of the title compound. Yield: 28.7% of theory Melting point: 81 C.

10
[ 95-77-2 ]
[ 156001-53-5 ]
[ 1355637-31-8 ]

Yield	Reaction Conditions	Operation in experiment
95%	With potassium carbonate; In acetone; at 75℃; for 18h;Inert atmosphere;	Preparation 605-Bromo-2-[(3,4-dichlorophenoxy)methyl1benzonitrileA mixture of 3,4-dichlorophenol (267.1 mg, 1 .639 mmol), 5-bromo-2- (bromomethyl)benzonitrile (447.3 mg, 1 .627 mmol), and potassium carbonate (674.1 mg, 4.877 mmol) in acetone (20 ml_) was heated to 75 C under nitrogen for 18 hours. The reaction mixture was cooled to room temperature, diluted with EtOAc (20 ml_) and filtered through arbocel. The arbocel was then washed with EtOAc (2 chi 20 ml_), and the combined organics were washed with brine (3 20 ml_), dried over sodium sulphate, filtered and concentrated in vacuo to afford the title compound as a white solid (549.9 mg, 95%).1H NMR (400 MHz, CDCI3): delta 5.18 (s, 2H), 6.86 (dd, 1 H), 7.1 1 (d, 1 H), 7.38 (d, 1 H),7.53 (d, 1 H), 7.78 (dd, 1 H), 7.86 (d, 1 H).LCMS Rt = 3.86 minutes MS m/z 356 [MH]+

Reference： [1]Patent: WO2012/7868,2012,A2 .Location in patent: Page/Page column 95

11
[ 529-19-1 ]
[ 156001-53-5 ]

Reference： [1]Journal of Materials Chemistry,2011,vol. 21,p. 9523 - 9531

12
[ 156001-53-5 ]
[ 1318689-68-7 ]

Reference： [1]Journal of Materials Chemistry,2011,vol. 21,p. 9523 - 9531

13
[ 156001-53-5 ]
[ 1318689-65-4 ]

Reference： [1]Journal of Materials Chemistry,2011,vol. 21,p. 9523 - 9531

14
[ 1272973-67-7 ]
[ 156001-53-5 ]
[ 1379522-59-4 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 5361 - 5379

15
[ 1272973-67-7 ]
[ 156001-53-5 ]
[ 1379522-45-8 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 5361 - 5379

16
[ 1394070-48-4 ]
[ 156001-53-5 ]
[ 1394071-38-5 ]

Yield	Reaction Conditions	Operation in experiment
57%		STEP A: 4-bromo-2-((2-chloro-6a,7,9,10-tetrahydro-[1,4]oxazino[3,4-h]pteridin-5(6H)-yl)methyl)benzonitrile To a 10 mL vial charged with 2-chloro-5,6,6a,7,9,10-hexahydro-[1,4]oxazino[3,4-h]pteridine (PREPARATION x2, 100 mg, 0.441 mmol) in DMSO (2.5 mL) was added sodium tert-butoxide (50.9 mg, 0.529 mmol). The resulting orange solution was stirred for 5 minutes, after which <strong>[156001-53-5]5-bromo-2-(bromomethyl)benzonitrile</strong> (133 mg, 0.485 mmol) was added. The reaction mixture was stirred overnight at room temperature, then diluted with EtOAc, and washed with saturated aq NH4Cl (3*). The combined organic layers were dried over MgSO4, filtered, and concentrated. The product was purified by flash chromatography (SiO2, 12 g column, 2:8 EtOAc/Hexane to 100% EtOAc gradient) to give the title compound as a brown foam (105 mg, 57%). 1H NMR (400 MHz, DMSO-d6) delta ppm 2.93-3.09 (m, 2H), 3.15 (s, 3H), 3.32 (s, 4H), 3.40-3.53 (m, 3H), 3.62-3.76 (m, 3H), 3.81-3.91 (m, 3H), 3.91-4.07 (m, 5H), 4.22-4.32 (m, 3H), 4.43-4.67 (m, 6H), 7.34 (s, 3H), 7.46 (d, J=8.34 Hz, 3H), 7.87 (dd, J=8.34, 2.02 Hz, 3H), 8.18 (d, J=2.02 Hz, 3H); ESI-MS m/z [M+H]+ calc'd for C17H15BrClN5O, 420.0. found 420.1.

Reference： [1]Patent: US2012/220575,2012,A1 .Location in patent: Page/Page column 40

17
(R)-2-(2-methyl-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)piperazin-1-yl)pyrimidin-5-ol [ No CAS ]
[ 156001-53-5 ]
(R)-5-bromo-2-((2-(2-methyl-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)piperazin-1-yl)pyrimidin-5-yloxy)methyl)benzonitrile [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 57,p. 8984 - 8998

18
[ 156001-53-5 ]
5-(methylsulfonyl)-2-[(2-{(2R)-2-methyl-4-[5-(trifluoromethyl)-1,3,4-oxadiazole-2-yl]piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}-benzonitrile [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 57,p. 8984 - 8998

19
[ 156001-53-5 ]
4-[(2-{(2R)-2-methyl-4-[5-(trifluoromethyl)-1,3,4-oxadiazole-2-yl]-piperazin-1-yl}pyrimidin-5-yl)oxy]methyl}benzene-1,3-dicarbonitrile [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 57,p. 8984 - 8998

20
[ 156001-53-5 ]
di-tert-butyl 2-cyano-4-(7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzylcarbamate [ No CAS ]

Reference： [1]Patent: WO2015/89327,2015,A1

21
[ 156001-53-5 ]
di-tert-butyl 2-cyano-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzylcarbamate [ No CAS ]

Reference： [1]Patent: WO2015/89327,2015,A1

22
[ 156001-53-5 ]
2-(aminomethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzonitrile [ No CAS ]

Reference： [1]Patent: WO2015/89327,2015,A1

23
[ 156001-53-5 ]
4-(tert-butyl)-N-(2-cyano-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)benzamide [ No CAS ]

Reference： [1]Patent: WO2015/89327,2015,A1

24
[ 156001-53-5 ]
4-(tert-butyl)-N-(2-carbamoyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)benzamide [ No CAS ]

Reference： [1]Patent: WO2015/89327,2015,A1

25
[ 156001-53-5 ]
5-(tert-butyl)-N-(2-cyano-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzyl)picolinamide [ No CAS ]

Reference： [1]Patent: WO2015/89327,2015,A1

26
[ 51779-32-9 ]
[ 156001-53-5 ]
tert-butyl N-[(4-bromo-2-cyanophenyl)methyl]-N-tert-butoxycarbonylcarbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
97%	With potassium carbonate; In acetonitrile; at 50℃; for 12h;	Step 2 To a solution of <strong>[156001-53-5]5-bromo-2-(bromomethyl)benzonitrile</strong> (4.4 g, 16.00 mmol, 1 eq) and tert-butyl N-tert-butoxycarbonylcarbamate (4.17 g, 19.20 mmol, 1.2 eq) in acetonitrile (50 mL) was added potassium carbonate (4.42 g, 32.01 mmol, 2 eq). The reaction mixture was stirred at 50 C. for 12 hours. LCMS showed most of <strong>[156001-53-5]5-bromo-2-(bromomethyl)benzonitrile</strong> was consumed. Water (100 mL) was added to the mixture, and the resulting mixture was extracted with ethyl acetate (50 mL*3). The combined organic phase was washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether:ethyl acetate=100:1 to 5:1). tert-Butyl N-[(4-bromo-2-cyano-phenyl)methyl]-N-tert-butoxycarbonyl-carbamate (6.4 g, 15.56 mmol, 97% yield) was obtained as a colorless oil.
37%		To a solution of Boc2NH (13 g, 58 mmol, 1.2 eq) in THF (150 mL) was added NaH (2.9 g, 73 mmol, 1.5 eq) at 0 C and the mixture was stirred at rt for 2 h. To the mixture was added 5-bromo-2- (bromomethyl)benzonitrile and the reaction was stirred at rt for 16 h, quenched upon the addition of water (250 mL), and extracted with EtOAc (250 mL * 3). The combined organics were washed with brine, dried, concentrated in vacuo to afford a solid which was purified by chromatography (petroleum ether EtOAc 10:1) to give the title compound (6.2 g, yield 37%) as a colorless oil. ESI-MS (M+H)+: 411.0

Reference： [1]Patent: US2019/300521,2019,A1 .Location in patent: Paragraph 1479-1480
[2]Patent: WO2015/89327,2015,A1 .Location in patent: Paragraph 0207

27
3-trityl-5-(tritylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-ol [ No CAS ]
[ 156001-53-5 ]
5-bromo-2-(((3-trityl-5-(tritylamino)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl)oxy)methyl)benzonitrile [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate; In dimethyl sulfoxide; at 20℃; for 1h;	245A: 5-Bromo-2-(((3-trityl-5-(tritylamino)-3H-[l,2,3]triazolo[4,5-b]pyridin-7- yl)oxy)methyl)benzonitrile [00345] DMSO (0.5 mL) was added to a vial containing Intermediate 5 (0.05 g, 0.08 mmol), <strong>[156001-53-5]5-bromo-2-(bromomethyl)benzonitrile</strong> (0.022 g, 0.079 mmol), and potassium carbonate (1 1 mg, 0.079 mmol) and the reaction mixture was stirred at rt for 1 h. Crude 245A was used in the next step to produce Example 245

Reference： [1]Patent: WO2017/40450,2017,A1 .Location in patent: Paragraph 00345

28
[ 156001-53-5 ]
4-(7-(3-cyano-4-(morpholinomethyl)phenyl)furo[3,2-b]pyridin-2-yl)-N,N-dimethylbenzamide [ No CAS ]

Reference： [1]Patent: US2016/376283,2016,A1

29
[ 156001-53-5 ]
4-(7-(3-cyano-4-(morpholinomethyl)phenyl)furo[3,2-b]pyridin-2-yl)-3-methoxy-N,N-dimethylbenzamide [ No CAS ]

Reference： [1]Patent: US2016/376283,2016,A1

30
[ 156001-53-5 ]
5-bromo-2-(dimethoxymethyl)benzonitrile [ No CAS ]

Reference： [1]Patent: US2017/362228,2017,A1

31
[ 156001-53-5 ]
tert-butyl 3-[3-cyano-4-(dimethoxymethyl)benzoyl]azetidine-1-carboxylate [ No CAS ]

Reference： [1]Patent: US2017/362228,2017,A1

32
[ 156001-53-5 ]
tert-butyl 3-[[3-cyano-4-(dimethoxymethyl)phenyl]hydroxymethyl]azetidine-1-carboxylate [ No CAS ]

Reference： [1]Patent: US2017/362228,2017,A1

33
[ 156001-53-5 ]
tert-butyl 3-[(3-cyano-4-formylphenyl)hydroxymethyl]azetidine-1-carboxylate [ No CAS ]

Reference： [1]Patent: US2017/362228,2017,A1

34
[ 156001-53-5 ]
tert-butyl 3-((4-((1R,3R)-2-(3-((tert-butyldiphenylsilyl)oxy)-2,2-difluoropropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-cyanophenyl)fluoromethyl)azetidine-1-carboxylate [ No CAS ]

Reference： [1]Patent: US2017/362228,2017,A1

35
[ 156001-53-5 ]
tert-butyl 3-((4-((1R,3R)-2-(3-((tert-butyldiphenylsilyl)oxy)-2,2-difluoropropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-cyanophenyl)(hydroxy)methyl)azetidine-1-carboxylate [ No CAS ]
tert-butyl 3-((4-((1S,3R)-2-(3-((tert-butyldiphenylsilyl)oxy)-2,2-difluoropropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3-cyanophenyl)(hydroxy)methyl)azetidine-1-carboxylate [ No CAS ]

Reference： [1]Patent: US2017/362228,2017,A1

36
[ 156001-53-5 ]
5-(azetidin-3-ylfluoromethyl)-2-((1R,3R)-2-(3-((tert-butyldiphenylsilyl)oxy)-2,2-difluoropropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)benzonitrile [ No CAS ]
5-(azetidin-3-ylfluoromethyl)-2-(cis-2-(3-((tert-butyldiphenylsilyl)oxy)-2,2-difluoropropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)benzonitrile [ No CAS ]

Reference： [1]Patent: US2017/362228,2017,A1

37
[ 156001-53-5 ]
2-(cis-2-(3-((tert-butyldiphenylsilyl)oxy)-2,2-difluoropropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-5-(fluoro(1-(3-fluoropropyl)azetidin-3-yl)methyl)benzonitrile [ No CAS ]

Reference： [1]Patent: US2017/362228,2017,A1

38
[ 156001-53-5 ]
5-bromo-2-(cyclohexylidenemethyl)benzonitrile [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

39
[ 156001-53-5 ]
N-(3'-cyano-4'-(cyclohexylidenemethyl)-2-(trifluoromethyl)biphenyl-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

40
[ 156001-53-5 ]
N-(3'-cyano-4'-(cyclohexylmethyl)-2-(trifluoromethyl)biphenyl-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

41
[ 156001-53-5 ]
2-((1-acetylpiperidin-4-ylidene)methyl)-5-bromobenzonitrile [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

42
[ 156001-53-5 ]
N-(4'-((1-acetylpiperidin-4-ylidene)methyl)-3'-cyano-2-(trifluoromethyl)biphenyl-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

43
[ 156001-53-5 ]
N-(4'-((1-acetylpiperidin-4yl)methyl)-3'-cyano-2-(trifluoromethyl)biphenyl-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

44
[ 156001-53-5 ]
5-bromo-2-((1-pivaloylpiperidin-4-ylidene)methyl)benzonitrile [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

45
[ 156001-53-5 ]
N-(3'-cyano-4'-((1-pivaloylpiperidin-4-ylidene)methyl)-2-(trifluoromethyl)biphenyl-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

46
[ 156001-53-5 ]
N-(3'-cyano-4'-((1-pivaloylpiperidin-4-yl)methyl)-2-(trifluoromethyl)biphenyl-4-yl)-2-(4-(ethylsulfonyl)phenyl)acetamide [ No CAS ]

Reference： [1]ACS Medicinal Chemistry Letters,2018,vol. 9,p. 120 - 124

47
[ 156001-53-5 ]
C₁₁H₁₃BrN₂O [ No CAS ]